Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor

Chun Hsu Pan, Ching Wen Chen, Ming Jyh Sheu, Chieh Hsi Wu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Salvianolic acid B (Sal B), a bioactive compound from Salvia miltiorrhiza, widely used to treat cardiovascular diseases, and stromal cell-derived factor-1α (SDF-1α)/CXCR4 pathway has been correlated with balloon angioplasty-induced neointimal formation. The purposes of the present study were to investigate whether Sal B can inhibit SDF-1α/CXCR4-mediated effects on the cell proliferation and migration of vascular smooth muscle cells (VSMCs) and to examine its possible molecular mechanisms. Under 0.5% FBS medium, all of the cellular studies were investigated on VSMCs (A10 cells) stimulated with 10. ng/ml SDF-1α alone or co-treated with 0.075. mg/ml Sal B. Our results showed that SDF-1α markedly stimulated the cell growth and migration of A10 cells, whose effects can be significantly reversed by co-incubation of Sal B. Similarly, Sal B also obviously down-regulated the SDF-1α-stimulated up-regulation of CXCR4 (total and cell-surface levels), Raf-1, MEK, ERK1/2, phospho-ERK1/2, FAK and phospho-FAK as well as an increase of the promoter activity of NF-κB. Besides, Sal B also effectively attenuated balloon angioplasty-induced neointimal hyperplasia. In conclusion, suppressing the expression levels of CXCR4 receptor and downstream molecules of SDF-1α/CXCR4 axis could possibly explain one of the pharmacological mechanisms of Sal B on prevention of cell proliferation, migration and subsequently neointimal hyperplasia.

Original languageEnglish
Pages (from-to)98-105
Number of pages8
JournalVascular Pharmacology
Volume56
Issue number1-2
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Fingerprint

CXCR4 Receptors
Chemokine CXCL12
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Movement
Cell Proliferation
Balloon Angioplasty
antineoplaston A10
Hyperplasia
Salvia miltiorrhiza
Mitogen-Activated Protein Kinase Kinases
salvianolic acid B
Cardiovascular Diseases
Up-Regulation
Pharmacology
Growth

Keywords

  • Salvianolic acid B
  • Stromal cell-derived factor-1α
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Physiology

Cite this

Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor. / Pan, Chun Hsu; Chen, Ching Wen; Sheu, Ming Jyh; Wu, Chieh Hsi.

In: Vascular Pharmacology, Vol. 56, No. 1-2, 01.2012, p. 98-105.

Research output: Contribution to journalArticle

@article{3ca10535247340f2b448a856d9a8b222,
title = "Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor",
abstract = "Salvianolic acid B (Sal B), a bioactive compound from Salvia miltiorrhiza, widely used to treat cardiovascular diseases, and stromal cell-derived factor-1α (SDF-1α)/CXCR4 pathway has been correlated with balloon angioplasty-induced neointimal formation. The purposes of the present study were to investigate whether Sal B can inhibit SDF-1α/CXCR4-mediated effects on the cell proliferation and migration of vascular smooth muscle cells (VSMCs) and to examine its possible molecular mechanisms. Under 0.5{\%} FBS medium, all of the cellular studies were investigated on VSMCs (A10 cells) stimulated with 10. ng/ml SDF-1α alone or co-treated with 0.075. mg/ml Sal B. Our results showed that SDF-1α markedly stimulated the cell growth and migration of A10 cells, whose effects can be significantly reversed by co-incubation of Sal B. Similarly, Sal B also obviously down-regulated the SDF-1α-stimulated up-regulation of CXCR4 (total and cell-surface levels), Raf-1, MEK, ERK1/2, phospho-ERK1/2, FAK and phospho-FAK as well as an increase of the promoter activity of NF-κB. Besides, Sal B also effectively attenuated balloon angioplasty-induced neointimal hyperplasia. In conclusion, suppressing the expression levels of CXCR4 receptor and downstream molecules of SDF-1α/CXCR4 axis could possibly explain one of the pharmacological mechanisms of Sal B on prevention of cell proliferation, migration and subsequently neointimal hyperplasia.",
keywords = "Salvianolic acid B, Stromal cell-derived factor-1α, Vascular smooth muscle cells",
author = "Pan, {Chun Hsu} and Chen, {Ching Wen} and Sheu, {Ming Jyh} and Wu, {Chieh Hsi}",
year = "2012",
month = "1",
doi = "10.1016/j.vph.2011.11.008",
language = "English",
volume = "56",
pages = "98--105",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor

AU - Pan, Chun Hsu

AU - Chen, Ching Wen

AU - Sheu, Ming Jyh

AU - Wu, Chieh Hsi

PY - 2012/1

Y1 - 2012/1

N2 - Salvianolic acid B (Sal B), a bioactive compound from Salvia miltiorrhiza, widely used to treat cardiovascular diseases, and stromal cell-derived factor-1α (SDF-1α)/CXCR4 pathway has been correlated with balloon angioplasty-induced neointimal formation. The purposes of the present study were to investigate whether Sal B can inhibit SDF-1α/CXCR4-mediated effects on the cell proliferation and migration of vascular smooth muscle cells (VSMCs) and to examine its possible molecular mechanisms. Under 0.5% FBS medium, all of the cellular studies were investigated on VSMCs (A10 cells) stimulated with 10. ng/ml SDF-1α alone or co-treated with 0.075. mg/ml Sal B. Our results showed that SDF-1α markedly stimulated the cell growth and migration of A10 cells, whose effects can be significantly reversed by co-incubation of Sal B. Similarly, Sal B also obviously down-regulated the SDF-1α-stimulated up-regulation of CXCR4 (total and cell-surface levels), Raf-1, MEK, ERK1/2, phospho-ERK1/2, FAK and phospho-FAK as well as an increase of the promoter activity of NF-κB. Besides, Sal B also effectively attenuated balloon angioplasty-induced neointimal hyperplasia. In conclusion, suppressing the expression levels of CXCR4 receptor and downstream molecules of SDF-1α/CXCR4 axis could possibly explain one of the pharmacological mechanisms of Sal B on prevention of cell proliferation, migration and subsequently neointimal hyperplasia.

AB - Salvianolic acid B (Sal B), a bioactive compound from Salvia miltiorrhiza, widely used to treat cardiovascular diseases, and stromal cell-derived factor-1α (SDF-1α)/CXCR4 pathway has been correlated with balloon angioplasty-induced neointimal formation. The purposes of the present study were to investigate whether Sal B can inhibit SDF-1α/CXCR4-mediated effects on the cell proliferation and migration of vascular smooth muscle cells (VSMCs) and to examine its possible molecular mechanisms. Under 0.5% FBS medium, all of the cellular studies were investigated on VSMCs (A10 cells) stimulated with 10. ng/ml SDF-1α alone or co-treated with 0.075. mg/ml Sal B. Our results showed that SDF-1α markedly stimulated the cell growth and migration of A10 cells, whose effects can be significantly reversed by co-incubation of Sal B. Similarly, Sal B also obviously down-regulated the SDF-1α-stimulated up-regulation of CXCR4 (total and cell-surface levels), Raf-1, MEK, ERK1/2, phospho-ERK1/2, FAK and phospho-FAK as well as an increase of the promoter activity of NF-κB. Besides, Sal B also effectively attenuated balloon angioplasty-induced neointimal hyperplasia. In conclusion, suppressing the expression levels of CXCR4 receptor and downstream molecules of SDF-1α/CXCR4 axis could possibly explain one of the pharmacological mechanisms of Sal B on prevention of cell proliferation, migration and subsequently neointimal hyperplasia.

KW - Salvianolic acid B

KW - Stromal cell-derived factor-1α

KW - Vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=84856252024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856252024&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2011.11.008

DO - 10.1016/j.vph.2011.11.008

M3 - Article

VL - 56

SP - 98

EP - 105

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 1-2

ER -